The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
BUSINESS
Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
Takeda Pharmaceutical will shake up its global R&D organization by integrating researchers scattered across the globe to selected sites in a bid to reinforce its research prowess and accelerate innovation in its three priority areas of GI, oncology, and CNS,…
To read the full story
Related Article
- As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
BUSINESS
- Daiichi Kicks Off PIII Quizartinib Study for FLT3-ITD Negative AML
December 12, 2024
- Kyowa Kirin to Globalize Research Organization after Orchard Buy
December 12, 2024
- Santen’s Glaucoma Drug Accepted for Review in Korea, Vietnam
December 12, 2024
- Eisai’s Gout Drug Urece Wins Nod in China
December 12, 2024
- ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…